DOCSLIB.ORG

Informe N°1 Mesa Nacional De Nuevas Sustancias Psicoactivas

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Informe N°1 Mesa Nacional De Nuevas Sustancias Psicoactivas MESA NACIONAL DE NUEVAS SUSTANCIAS PSICOACTIVAS “Coordinación, recopilación y análisis interinstitucional de la información disponible para la actualización de los listados de drogas” Informe N° 1, septiembre 2015 Introducción La oferta de drogas es un problema dinámico, lo que se refleja entre otras cosas por la aparición constante de nuevas sustancias psicoactivas (NSP) y el riesgo a la salud pública y seguridad ciudadana que estas representan. Las NSP han aumentado su presencia, diversificando sus mercados y señalando nuevos desafíos para las políticas públicas que buscan enfrentar el problema mundial de las drogas. La información disponible muestra que las incautaciones realizadas por las policías se han incrementado en los últimos años, siendo el 2014 el período con mayor número de dosis decomisadas. A modo de ejemplo las incautaciones de NBOMes el 2013 alcanzaron las 2.245 dosis y el 2014 alcanzaron las 22.222 dosis, lo que representa un crecimiento aproximado de 1.000%. La Subsecretaria del Interior, a través del Departamento de Sustancias Químicas Controladas de la División de Estudios, convocó a la Mesa Nacional de Nuevas Sustancias Psicoactivas, la cual se constituyó el 31 de marzo de 2015, con el objetivo de realizar un análisis interinstitucional que permita estudiar las NSP aparecidas tanto en Chile como el exterior, emitiendo un informe que determine la pertinencia (química-jurídica y política criminal) de incorporar dichas drogas a los listados nacionales. El trabajo de la mesa se desarrolló en tres grupos de expertos, los que analizaron familias de nuevas sustancias como son los cannabinoides sintéticos, las catinanonas sintéticas y las piperazinas. Sus resultados se ven reflejados en este informe final, que constituye el primero de la mesa y un avance importante para el control de estas drogas. Finalmente, agradecer a los líderes de cada uno de los grupos y a todos los funcionarios de las instituciones participantes. Departamento de Sustancias Químicas Controladas 2 Instituciones 3 Funcionarios participantes Ministerio de Salud: Químico Farmacéutico del Departamento de Políticas Farmacéuticas y Profesiones Médicas, Juan Arellano Mañan. Químico Farmacéutico, Karem Castillo Arteaga. Químico Farmacéutico, Cristian Matamala. Ministerio de Relaciones Exteriores: Abogada de la Dirección de Seguridad Internacional y Humana (DISIN) Consuelo Novoa Fernández. Analista de la DISIN, Eduardo Pool Rubio. Fiscalía Nacional: Director (s) Unidad Especializada en Tráfico Ilícito de Estupefacientes y Sustancias Sicotrópicas, Alejandro Ivelic Mancilla. Subdirectora Unidad Especializada en Tráfico Ilícito de Estupefacientes y Sustancias Sicotrópicas, Lorena Rebolledo Latorre. Instituto de Salud Pública (ISP): Jefe (S) Departamento Salud Ambiental, Iván Triviño Angulo. Perito Químico de la Sección de Análisis de Drogas, Sonia Rojas Rondón. Servicio Médico Legal: Jefa (S) Departamento de Laboratorios, Sylvia Miranda Arismendi. Químico Farmacéutico, Adolfo Gálvez Palma. Químico Farmacéutico, Ximena Godoy Ávila. Químico Farmacéutico, Marcos Bastías Contreras. Químico Farmacéutico, Cristian Chacana Santana. Químico Farmacéutico, Eddie Vargas Mondaca. Servicio Nacional para la Prevención y Rehabilitación del Consumo de Drogas y Alcohol (SENDA): Jefe Departamento de Estudios, Álvaro Castillo Carniglia. Asesor Departamento de Estudios, José Marín Montecinos. Servicio Nacional de Aduanas: Departamento de Fiscalización de Drogas, Carlos Sepúlveda González. Químico Industrial de la Subdirección Técnica del Departamento Laboratorio Químico, Trinidad Maldonado Acosta. Profesional Químico, Marcela Cárdenas Águila. Carabineros de Chile: Teniente Coronel Manuel Cifuentes Quezada del OS-7. Capitán del OS-7, Sebastián Muñoz Rojas. Sociólogo del OS7, Anton Lázaro Muller. Químico Farmacéutico de Labocar, Carla Hidalgo Figueroa. Dirección General del Territorio Marítimo y de Marina Mercante (Directemar): Jefe División de Narcotráfico, Juan Rojas Méndez. Departamento de Inteligencia Marítima, Patricio Concha Alvear. Analista, Ricardo Arredondo Auristondo Policía de Investigaciones de Chile: Departamento de Investigación de Sustancias Químicas Controladas DISUQ, Subcomisario Patricio Navarro Poblete. Subcomisario Gonzalo Santander. Departamento de Sustancias Químicas Controladas (DSQC): Jefe, Sebastián Perelló Enrich. Abogado, Tomás Razazi Aylwin. Abogado, Edmundo Esbry Arteaga. Fiscalizador y Químico Farmacéutico, Luis Medel Espinoza. Fiscalizador y Químico Farmacéutico, Javier Rivera Peralta. Encargada de Comercio Exterior, Nazareth Garrao Godoy. 4 Índice Introducción ........................................................................................................................................ 2 Instituciones ....................................................................................................................................... 3 Funcionarios participantes ................................................................................................................. 4 Resumen ejecutivo ............................................................................................................................ 6 Grupo de Experto N° 1, Cannabinoides Sintéticos .......................................................................... 10 NSP: AM-2201 y análogos ................................................................................................................. 11 NSP: APINACA y análogos.................................................................................................................. 25 Grupo de Experto N° 2, Catinonas Sintéticas................................................................................... 37 NSP : Butilona .................................................................................................................................... 38 NSP : Dimetilona ............................................................................................................................... 46 NSP : Metilona y análogos ................................................................................................................ 54 NSP : Mefedrona y análogos ............................................................................................................ 65 NSP : Metilendioxipirovalerona y análogos ...................................................................................... 78 Grupo de Experto N° 3, Piperazinas. ................................................................................................ 90 NSP : BZP, m-CPP, TFMPP.................................................................................................................. 91 5 Resumen Ejecutivo Luego del trabajo realizado en la Mesa Nacional de Nuevas Sustancias Psicoactivas entre el 31 de marzo y el 28 de septiembre del año 2015, los expertos de los tres grupos elaboran la siguiente recomendación: a) Incluir en la lista del artículo 1 del Decreto Supremo N° 867, que contiene aquellas sustancias que producen dependencia física o psíquica, capaces de producir graves efectos tóxicos o daños considerables a la salud, las siguientes sustancias psicoactivas: CATINONAS SINTETICAS N° Nombre Común Nombre IUPAC o Nombre Químico 1 Metilona 2-metilamino-1-(3,4-metilendioxifenil)-1-propanona 2 Etilona 2-etilamino-1-(3,4-metilendioxifenil)-1-propanona 3 Dimetilona 2-dimetilamino-1-(3,4-metilendioxifenil)-1-propanona 4 Butilona 2-metilamino-1-(3,4-metilendioxifenil)-1-butanona 5 Dibutilona 2-dimetilamino-1-(3,4-metilendioxifenil)-1-butanona 6 Eutilona 2-etilamino-1-(3,4-metilendioxifenil)-1-butanona 7 Pentilona 2-metilamino-1-(3,4-metilendioxifenil)-1-pentanona 8 Propilbutilona 2-propilamino-1-(3,4-metilendioxifenil)-1-butanona 9 BMDB 2-bencilamino-1-(3,4-metilendioxifenil)-1-butanona 10 BMDP 2-bencilamino-1-(3,4-metilendioxifenil)-1-propanona 11 Mefedrona 2-metilamino-1-(4-metilfenil)-1-propanona 6 12 Metedrona 2-metilamino-1-(4-metoxifenil) -1-propanona 13 Flefedrona 2-metilamino-1-(4-fluorofenil)-1-propanona 14 Fluorometcatinona 2-metilamino-1-(3-fluorofenil)-1-propanona 15 Etilmetcatinona 2-metilamino-1-(fenil)-1-propanona 16 Dimetilmetcatinona 2-metilamino-1-(3,4-dimetilfenil)-1-propanona 17 Etilbufedrona 2-etilamino-1-(fenil)-1-butanona 18 Pentedrona 2-metilamino-1-(fenil)-1-pentanona 19 3-Metilmetcatinona 2-metilamino-1-(3-metilfenil)-1-propanona 20 Metiletcatinona 2-etilamino-1-(4-metilfenil)-1-propanona 21 Bufedrona 2-metilamino-1-(fenil)-1-butanona 22 Dimetilpropion 2-dimetilamino-1-(fenil)-1-propanona 23 Etilpropion 2-etilamino-1-(fenil)-1-propanona 24 Isopentedrona 2-(metilamino)-1-fenil-2-pentanona 25 MDPV 1-(3,4-metilendioxifenol)-2-pirrolidinil-1-pentanona 26 MDMPP 1-(3,4-metilenedioxifenil)-2-metil-2-pirrolidinil-1-propanona 27 MDPPP 1-(3,4-metilendioxifenil)-2-(1-pirrolidinil)-1-propanona 28 MDPBP 1-(3,4-metilendioxifenil)-2-(1-pirrolidinil)-1-butanona 29 Nafirona 1-naftaleno-2-il-(2-pirrolidinil)-1-pentanona 30 Alfa PVP 1-fenil-2-(1-pirrolidinil)-1-pentanona CANNABINOIDES SINTETICOS 7 31 AM-2201 (naftalen-1-il) [1-(5-fluoropentil)-1H-indol-3-il] metanona (4-metilnaftalen-1-il)[1-(5-fluoropentil)- 1H-indol-3-il] 32 MAM-2201 metanona 33 AM-2201 Indazol (naftalen-1-il) [1-(5-fluoropentil)-1H-indazol-3-il] metanona AM-2201 (naftalen-1-il) [1-(5-fluoropentill)-1H-benzo[d]imidazol-2-il) 34 benzimidazol metanona 35 JWH-122 (4-metilnaftalen-1-il) (1-pentil-1H-indol- 3-il) metanona 36 THJ-018 (naftalen-1-il) [ 1-pentil-1H-indazol-3-ill) metanona (4-etilnaftalen-1-il) [1-(5-fluoropentil)-1H-indol-3-il]
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Exploring Pharmacological Significance and Reaction Dynamics of Piperazinemoiety
    Exploring Pharmacological Significance and Reaction Dynamics of PiperazineMoiety. Rajashree A. Markandewar 1, S R Deshmukh 2 and M.A Baseer 3 1,2 Dept. of Chemistry, R. M. G.Mahavidyalaya, Saoli, Dist Chandrapur-441225 3Dept. of Chemistry, YeshwantMahavidyalaya, Nanded- 431602 Abstract: Piperazines and their analogs are amongst the most important backbones in today’s drug discovery industries. The purpose of this paper is to provide an overview of the pharmacological properties of piperazines and Reaction dynamics. The synthesis of of 4-(4- methyl piperazine-l-yl) benzaldehyde a variety of Nitrogen containing aldehyde is described with proper choice of base, solvent and temperature conditions. This work is underway to ameliorate difficulties which remain, especially in finding suitable reaction dynamics that efficiently increases the yield. The synthesized compounds were characterized by IR, 1HNMR and MS Spectroscopy. Keywords: Piperazines Nitrogen-containing-aldehyde, Reaction dynamics, N-arylation . Introduction: Synthetic chemistry provides corpucopia of heterocyclic systems. More than 90% of new drugs contain heterocycles and the interface between chemistry and biology. The modern day medicinal chemistry is based on heterocyclic molecules and we owe to them, due to their close association with numerous biological as well as pharmacological activities. Nitrogen containing heterocycles is subunit found in numerous natural products and in many biologically active pharmaceuticals [1]. An important aspect of medicinal chemistry is to establish as relationship between chemical structure and pharmacological activity. Piperazine is a sex membered ring structure containing twoopposing nitrogen atoms. Nitrogen containing compounds is used as structural components of pharmaceuticals and agrochemicals due to their high biological activities. There are many nitrogen containing chemicals, ranging from simple structural compounds as pyridine to complicated compounds as pharmaceuticals ingredients and their number is growing rapidly year by year [2].
    [Show full text]
  • "Official Gazette of RM", No. 28/04 and 37/07), the Government of the Republic of Montenegro, at Its Meeting Held on ______2007, Enacted This
    In accordance with Article 6 paragraph 3 of the FT Law ("Official Gazette of RM", No. 28/04 and 37/07), the Government of the Republic of Montenegro, at its meeting held on ____________ 2007, enacted this DECISION ON CONTROL LIST FOR EXPORT, IMPORT AND TRANSIT OF GOODS Article 1 The goods that are being exported, imported and goods in transit procedure, shall be classified into the forms of export, import and transit, specifically: free export, import and transit and export, import and transit based on a license. The goods referred to in paragraph 1 of this Article were identified in the Control List for Export, Import and Transit of Goods that has been printed together with this Decision and constitutes an integral part hereof (Exhibit 1). Article 2 In the Control List, the goods for which export, import and transit is based on a license, were designated by the abbreviation: “D”, and automatic license were designated by abbreviation “AD”. The goods for which export, import and transit is based on a license designated by the abbreviation “D” and specific number, license is issued by following state authorities: - D1: the goods for which export, import and transit is based on a license issued by the state authority competent for protection of human health - D2: the goods for which export, import and transit is based on a license issued by the state authority competent for animal and plant health protection, if goods are imported, exported or in transit for veterinary or phyto-sanitary purposes - D3: the goods for which export, import and transit is based on a license issued by the state authority competent for environment protection - D4: the goods for which export, import and transit is based on a license issued by the state authority competent for culture.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson Et Al
    US006319953B1 (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson et al. (45) Date of Patent: *Nov. 20, 2001 (54) TREATMENT OF DEPRESSION AND WO 95/08549 3/1995 (W0). ANXIETY WITH FLUOXETINE AND AN WO 95/18124 7/1995 (W0). NK-1 RECEPTOR ANTAGONIST W0 96/05181 2/1996 (W0). W0 96/18643 6/1996 (W0). (75) Inventors: Emma Joanne Carlson, Puckeridge; W0 96/19233 6/1996 (W0). Nadia Melanie Rupniak, Bishops W0 96/24353 8/1996 (W0). W0 98/15277 4/1998 (W0). Stortford, both of (GB) OTHER PUBLICATIONS (73) Assignee: Merck Sharp & Dohme Ltd., Hoddesdon (GB) Aguiar, M., et al., Physiology& Behavior, 1996, 60(4) 1183—1186. ( * ) Notice: Subject to any disclaimer, the term of this Barden, N., et al., J. Neurochem., 1983, 41, 834—840. patent is extended or adjusted under 35 BristoW, L., et al., Eur J. Pharmacol., 1994, 253, 245—252. U.S.C. 154(b) by 0 days. Brodin, E., et al., Neuropharmacology, 1987, 26(6) 581—590. This patent is subject to a terminal dis Brodin, E., et al., Neuropeptides, 1994, 26, 253—260. claimer. Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885—891. Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87. (21) Appl. N0.: 09/457,241 Elliott, P. J., Exp. Brain Res. UK, 1988, 73, 354—356. (22) Filed: Dec. 8, 1999 F—D—C Reports—Prescription Pharmaceuticals and Bio technology, Dec. 8, 1997, 59(49), 10. Related US. Application Data File, S. E., Pharm. Biochem. Behavior, 1997, 58, 3, 747—752. (60) Division of application No.
    [Show full text]
  • Toxic, and Comatose-Fatal Blood-Plasma Concentrations (Mg/L) in Man
    Therapeutic (“normal”), toxic, and comatose-fatal blood-plasma concentrations (mg/L) in man Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Abacavir (ABC) 0.9-3.9308 appr. 1.5 [1,2] Acamprosate appr. 0.25-0.7231 1311 13-20232 [3], [4], [5] Acebutolol1 0.2-2 (0.5-1.26)1 15-20 3-11 [6], [7], [8] Acecainide see (N-Acetyl-) Procainamide Acecarbromal(um) 10-20 (sum) 25-30 Acemetacin see Indomet(h)acin Acenocoumarol 0.03-0.1197 0.1-0.15 3-11 [9], [3], [10], [11] Acetaldehyde 0-30 100-125 [10], [11] Acetaminophen see Paracetamol Acetazolamide (4-) 10-20267 25-30 2-6 (-13) [3], [12], [13], [14], [11] Acetohexamide 20-70 500 1.3 [15] Acetone (2-) 5-20 100-400; 20008 550 (6-)8-31 [11], [16], [17] Acetonitrile 0.77 32 [11] Acetyldigoxin 0.0005-0.00083 0.0025-0.003 0.005 40-70 [18], [19], [20], [21], [22], [23], [24], [25], [26], [27] 1 Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Acetylsalicylic acid (ASS, ASA) 20-2002 300-3502 (400-) 5002 3-202; 37 [28], [29], [30], [31], [32], [33], [34] Acitretin appr. 0.01-0.05112 2-46 [35], [36] Acrivastine -0.07 1-2 [8] Acyclovir 0.4-1.5203 2-583 [37], [3], [38], [39], [10] Adalimumab (TNF-antibody) appr. 5-9 146 [40] Adipiodone(-meglumine) 850-1200 0.5 [41] Äthanol see Ethanol -139 Agomelatine 0.007-0.3310 0.6311 1-2 [4] Ajmaline (0.1-) 0.53-2.21 (?) 5.58 1.3-1.6, 5-6 [3], [42] Albendazole 0.5-1.592 8-992 [43], [44], [45], [46] Albuterol see Salbutamol Alcuronium 0.3-3353 3.3±1.3 [47] Aldrin -0.0015 0.0035 50-1676 (as dieldrin) [11], [48] Alendronate (Alendronic acid) < 0.005322 -6 [49], [50], [51] Alfentanil 0.03-0.64 0.6-2.396 [52], [53], [54], [55] Alfuzosine 0.003-0.06 3-9 [8] 2 Substance Blood-plasma concentration (mg/L) t½ (h) Ref.
    [Show full text]
  • World Journal of Pharmaceutical Research SJIF Impact Factor 6.805 Mark Andewar Et Al
    World Journal of Pharmaceutical Research SJIF Impact Factor 6.805 Mark andewar et al. World Journal of Pharmaceutical Research Volume 5, Issue 7, 1409-1420. Research Article ISSN 2277– 7105 EXPLORING PHARMACOLOGICAL SIGNIFICANCE OF PIPERAZINE SCAFFOLD Rajashree A. Markandewar1* and M. A. Baseer2 1Department of Chemistry, Rashtrapita Mahatma Gandhi Mahavidyalaya, Saoli, Dist Chandrapur-441225. 2Department of Chemistry, Yeshwant Mahavidyalaya, Nanded-431601. ABSTRACT Article Received on 15 May 2016, Piperazines and their heterocyclic analogues possess a number of Revised on 05 June 2016, interesting biological properties. Clinical trials have shown that these Accepted on 26 June 2016 compounds reached reasonable plasma concentration and are well- DOI: 10.20959/wjpr20167-6606 tolerated. For this reason they are an object of continuously growing interest amongst the scientists. The purpose of this review is to provide *Corresponding Author an overview of the pharmacological properties as well as therapeutic Rajashree A. Markandewar applications of piperazine depending upon the pattern of substitution Department of Chemistry, on the piperazine ring and their presence in many widely used drugs. Rashtrapita Mahatma This article highlights an interrelationship of yield and other reaction Gandhi Mahavidyalaya, dynamics for piperazine moity. Saoli, Dist Chandrapur- KEYWORDS: Heterocycles, Piperazines, drugs containing piperazine 441225. ring. INTRODUCTION Heterocycles are inextricably woven into life processes. Synthetic chemistry provides corpucopia
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Video Course Evaluation Form My Name Is
    Garden State CLE 2000 Hamilton Avenue Hamilton, New Jersey 08619 (609) 584-1924 – Phone (609) 584-1920 - Fax Video Course Evaluation Form My Name is: __________________________________________ Name of Course: ______________________________________ My Street address: _____________________________________ City: _____________________ State: _____ Zip Code: ____ Email Address: ________________________________________ Please Circle the Appropriate Answer Instructors: Poor Satisfactory Good Excellent Materials: Poor Satisfactory Good Excellent CLE Rating: Poor Satisfactory Good Excellent Required: Secret words that appeared on the screen during the seminar. 1) __________________________ 2) _______________________ 3) __________________________ 4) _______________________ What did you like most about the seminar? _____________________________________________________________ _____________________________________________________________ What criticisms, if any, do you have? _____________________________________________________________ _____________________________________________________________ I certify that I watched, in its entirety, the above-listed CLE Course. Signature ___________________________________ Date_________ In order to receive your CLE credits, please send our payment and this completed form to Garden State CLE, 2000 Hamilton Avenue, Hamilton, New Jersey, 08619. BURLINGTON COUNTY BAR ASSOCIATION --- Interpreting Your Client’s Drug Lab Results: Were They Impaired? © Chris Baxter 2020 DO LAB RESULTS MATTER IN A DUI-D? YES ➢State
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 21.8018.02000 FIRST ENGROSSMENT Sixty-Seventh Legislative Assembly ENGROSSED SENATE BILL NO
    21.8018.02000 FIRST ENGROSSMENT Sixty-seventh Legislative Assembly ENGROSSED SENATE BILL NO. 2059 of North Dakota Introduced by Judiciary Committee (At the request of the State Board of Pharmacy) 1 A BILL for an Act to amend and reenact subsection 18 of section 19-03.1-01 and sections 2 19-03.1-05, 19-03.1-07, 19-03.1-11 and 19-03.1-13 of the North Dakota Century Code, relating 3 to the definition of marijuana and the scheduling of controlled substances; and to declare an 4 emergency. 5 BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA: 6 SECTION 1. AMENDMENT. Subsection 18 of section 19-03.1-01 of the North Dakota 7 Century Code is amended and reenacted as follows: 8 18. "Marijuana" means all parts of the plant cannabis sativa L., whether growing or not; 9 the seeds thereof; the resin extracted from any part of the plant; and every compound, 10 manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or resin. 11 The term does not include the mature stalks of the plant, fiber produced from the 12 stalks, oil or cake made from the seeds of the plant, any other compound, 13 manufacture, salt, derivative, mixture, or preparation of mature stalks, except the resin 14 extracted therefrom, fiber, oil, or cake, or the sterilized seed of the plant which is 15 incapable of germination. The term marijuana does not include hemp as defined in 16 title 4.1means all parts of the plant cannabis sativa L., whether growing or not; the 17 seeds thereof; the resin extracted from any part of the plant; and every compound, 18 manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or resin.
    [Show full text]